Edetic Acid

Edetic Acid

SCHEMBL68140

O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.OB(O)O.OB(O)O.OB(O)O

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.82
EYA2 O00167 1/20 0.82
APP P05067 1/20 0.82
ACE P12821 1/20 0.82
BLM P54132 2/20 0.78
PMP22 Q01453 2/20 0.78
KDM4E B2RXH2 2/20 0.78
ALOX15 P16050 2/20 0.78
TSHR P16473 2/20 0.78
LMNA P02545 1/20 0.78
CHRM2 P08172 1/20 0.78
ADRA2A P08913 1/20 0.78
DRD1 P21728 1/20 0.78
SLC6A2 P23975 1/20 0.78
SLC6A4 P31645 1/20 0.78
CYP2C19 P33261 1/20 0.78
ADRA1A P35348 1/20 0.78
DRD3 P35462 1/20 0.78
SLC6A3 Q01959 1/20 0.78
HRH3 Q9Y5N1 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Edetic Acid SCHEMBL20955 1.00 TDP1 (0.82) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL6684859 0.92 TDP1 (0.70) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL1373 0.91 TDP1 (1.00) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL8607480 0.91 TDP1 (1.00) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL16714076 0.91 TDP1 (1.00) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL3035039 0.91 TDP1 (1.00) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL8624198 0.91 TDP1 (1.00) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL15136 0.91 TDP1 (1.00) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL16570043 0.90 TDP1 (0.67) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL10542859 0.88 TDP1 (0.93) TDP1EYA2APPACEBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240200038-A1 METHOD FOR SEPARATING AND PURIFYING INFLUENZA VIRUS-LIKE PARTICLES (VLPS) USING AQUEOUS TWO-PHASE SYSTEM (ATPS) ZJ Huadi Pharma Group Pharma Development Co., Ltd. (CN) 2024-06-20 US claimed
US-11926877-B2 Saliva-based molecular testing for SARS-CoV-2 THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-03-12 US claimed
US-20230378297-A1 Source/Drains In Semiconductor Devices and Methods of Forming Thereof TAIWAN SEMICONDUCTOR MFG CO LTD (TW) 2023-11-23 US claimed
US-11530457-B2 Saliva-based molecular testing for SARS-CoV-2 THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2022-12-20 US claimed
WO-2021257844-A1 SALIVA-BASED MOLECULAR TESTING FOR SARS-COV-2 THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2021-12-23 WO claimed
US-20210395839-A1 SALIVA-BASED MOLECULAR TESTING FOR SARS-COV-2 THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2021-12-23 US claimed
EP-2300799-B1 METHOD FOR HISTOCHEMICAL PROCESSESSING AND USE OF A COMPOSITION FOR HISTOCHEMICAL PROCESSING VENTANA MED SYST INC (US) 2015-11-25 EP claimed
WO-2024148013-A1 COMPOSITIONS, KITS AND METHODS FOR DETECTION OF VIRAL SEQUENCES Life Technologies Corporation (US) 2024-07-11 WO disclosed
US-20240200038-A1 METHOD FOR SEPARATING AND PURIFYING INFLUENZA VIRUS-LIKE PARTICLES (VLPS) USING AQUEOUS TWO-PHASE SYSTEM (ATPS) ZJ Huadi Pharma Group Pharma Development Co., Ltd. (CN) 2024-06-20 US disclosed
US-20240186188-A1 SEMICONDUCTOR DEVICE WITH NON-CONFORMAL GATE DIELECTRIC LAYERS TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2024-06-06 US disclosed
US-11965164-B2 Amphiphilic polynucleotides DUKE UNIVERSITY (US) 2024-04-23 US disclosed
US-11926877-B2 Saliva-based molecular testing for SARS-CoV-2 THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-03-12 US disclosed
US-11908745-B2 Semiconductor device with non-conformal gate dieletric layers TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2024-02-20 US disclosed
US-5958202-A BINDING ANALYTE TO ENZYME HAVING A BIORECOGNITION MOIETY AND ELECTROPHORETIC SEPARATION, ENZYME AMPLIFIED DETECTION PERSEPTIVE BIOSYSTEMS, INC. (US) 1999-09-28 US disclosed
US-5922185-A System for pH-neutral stable electrophoresis gel NOVEL EXPERIMENTAL TECHNOLOGY, INC. (US) 1999-07-13 US disclosed
EP-0854937-A1 METHODS AND KIT FOR HYBRIDIZATION ANALYSIS USING PEPTIDE NUCLEIC ACID PROBES PERSEPTIVE BIOSYSTEMS, INC. (US) 1998-07-29 EP disclosed
WO-1997012995-A1 METHODS AND KIT FOR HYBRIDIZATION ANALYSIS USING PEPTIDE NUCLEIC ACID PROBES PERSEPTIVE BIOSYSTEMS, INC. (US) 1997-04-10 WO disclosed
US-4833086-A PLASMIDS, POLLUTION CONTROL, CULTURE OF ALCALIGENES, ETHYLENE DCHLORIDE THE B F GOODRICH COMPANY (US) 1989-05-23 US disclosed
US-4806482-A CULTURING PLASMID OF ALCALIGENES; GENE ENCODING; TOXIC WASTES CONTROL; ETHYLENE DICHLORIDE THE B.F. GOODRICH COMPANY (US) 1989-02-21 US disclosed
EP-0241746-A2 Microbial degradation of hydrocarbons The B.F. GOODRICH Company (US) 1987-10-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11965164-B2 Amphiphilic polynucleotides NCL, APLNR, POLN TDP1 408/4885EYA2 2420/4885APP 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.